Generation of Healthy Mice from Gene-Corrected Disease-Specific Induced Pluripotent Stem Cells by Wu, Guangming et al.
Generation of Healthy Mice from Gene-Corrected
Disease-Specific Induced Pluripotent Stem Cells
Guangming Wu
1., Na Liu
1,2., Ina Rittelmeyer
3, Amar Deep Sharma
2, Malte Sgodda
2, Holm Zaehres
1,
Martina Bleidißel
1, Boris Greber
1, Luca Gentile
1, Dong Wook Han
1,4, Cornelia Rudolph
5, Doris
Steinemann
5, Axel Schambach
6, Michael Ott
3, Hans R. Scho ¨ler
1,2,7, Tobias Cantz
1,2*
1Max-Planck-Institute for Molecular Biomedicine, Mu ¨nster, Germany, 2Junior Research Group Stem Cell Biology, Cluster of Excellence REBIRTH, Hannover Medical School,
Hannover, Germany, 3Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, and TWINCORE Centre for Experimental and Clinical
Infection Research, Hannover, Germany, 4Department of Stem Cell Biology, Konkuk University, Seoul, Republic of Korea, 5Junior Research Group Genetic & Epigenetic
Integrity, Cluster of Excellence REBIRTH, Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany, 6Junior Research Group Hematopoietic
Cell Therapy, Cluster of Excellence REBIRTH, Department Experimental Hematology, Hannover Medical School, Hannover, Germany, 7Medical Faculty, University of
Mu ¨nster, Mu ¨nster, Germany
Abstract
Using the murine model of tyrosinemia type 1 (fumarylacetoacetate hydrolase [FAH] deficiency; FAH
2/2 mice) as a paradigm
for orphan disorders, such as hereditary metabolic liver diseases, we evaluated fibroblast-derived FAH
2/2-induced
pluripotent stem cells (iPS cells) as targets for gene correction in combination with the tetraploid embryo complementation
method. First, after characterizing the FAH
2/2 iPS cell lines, we aggregated FAH
2/2-iPS cells with tetraploid embryos and
obtained entirely FAH
2/2-iPS cell–derived mice that were viable and exhibited the phenotype of the founding FAH
2/2 mice.
Then, we transduced FAH cDNA into the FAH
2/2-iPS cells using a third-generation lentiviral vector to generate gene-
corrected iPS cells. We could not detect any chromosomal alterations in these cells by high-resolution array CGH analysis,
and after their aggregation with tetraploid embryos, we obtained fully iPS cell–derived healthy mice with an astonishing
high efficiency for full-term development of up to 63.3%. The gene correction was validated functionally by the long-term
survival and expansion of FAH-positive cells of these mice after withdrawal of the rescuing drug NTBC (2-(2-nitro-4-
fluoromethylbenzoyl)-1,3-cyclohexanedione). Furthermore, our results demonstrate that both a liver-specific promoter
(transthyretin, TTR)-driven FAH transgene and a strong viral promoter (from spleen focus-forming virus, SFFV)-driven FAH
transgene rescued the FAH-deficiency phenotypes in the mice derived from the respective gene-corrected iPS cells. In
conclusion, our data demonstrate that a lentiviral gene repair strategy does not abrogate the full pluripotent potential of
fibroblast-derived iPS cells, and genetic manipulation of iPS cells in combination with tetraploid embryo aggregation
provides a practical and rapid approach to evaluate the efficacy of gene correction of human diseases in mouse models.
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Introduction
Direct reprogramming of somatic cells into induced pluripotent
stem (iPS) cells has been achieved by the expression of the four
factors Oct4, Sox2, Klf4, and c-Myc (or of Oct4, Sox2, Nanog,
and Lin28) in mice and humans [1–4]. This new technology offers
a promising approach for the derivation of disease-specific iPS
cells for basic and regenerative medicine research. The technique
was first successfully used in a murine sickle cell anemia model [5],
demonstrating that gene-corrected iPS cell–derived hematopoietic
progenitor cells ameliorated, but did not fully normalize, the
phenotype associated with this chronic red blood cell disorder.
Various human disease-specific iPS cell lines have been generated
[6] either for disease modeling [7–16] or for cell transplantation in
preclinical models [17–20]. However, to date, no report has
demonstrated that a full pluripotent phenotype is maintained in
gene-corrected iPS cells, which is of particular importance
considering the controversy regarding the slightly different
differentiation capabilities of iPS and ES cells [21,22] and the
genetic or epigenetic stability of human iPS cells [23–26]. These
studies have found numerous molecular changes in human iPS
cells: chromosomal abnormalities (increased copy number alter-
ations, CNAs), multiple point mutations (partly acquired during
the early phase of reprogramming), and aberrant methylation of
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correlation between such (epi)genetic alterations and different
reprogramming methods has been found, and it remains fairly
unclear how those changes affect the functionality of pluripotent
stem cells. Therefore, more robust assays to better assess the
pluripotency of human and murine iPS cells are needed.
The most stringent test for pluripotency is tetraploid comple-
mentation, which uses tetraploid (4n) embryos as host embryos for
injection or aggregation with ES cells, resulting in offspring that
are entirely derived of ES cells in a single step [27–29]. We
therefore consider the tetraploid complementation as the state-of-
the-art technique to assess the pluripotency of a given cell line, as
an organism that has been fully derived from only the cells in
question will exhibit their full potential. Wernig et al. utilized this
approach to analyze iPS cell–derived fetuses of embryonic day (E)
12.5 [3], but they could not obtain live-born pups. More recently,
three groups reported the generation of mice from 4-factor
reprogrammed non-diseased iPS cells to adulthood [30–32]. Most
recently, Stadtfeld et al. used tetraploid embryo complementation
to demonstrate that aberrant silencing of the Dlk1-Dio cluster on
chromosome 12 is the distinguishing characteristic of murine iPS
cells capable of contributing to full-term development, versus those
incapable [33]. But it is not known whether genetic manipulation
and prolonged propagation of iPS cells impairs their potential to
support full-term embryo development.
In this study, we derived iPS cells from the fibroblasts of FAH
2/2
mice, a mouse model of the acute and life-threatening disease
tyrosinemia type 1 (fumarylacetoacetate hydrolase [FAH] deficien-
cy) in humans [34], which we considered as a paradigm for an iPS
cell–based gene therapy approach for orphan diseases, such as
severe metabolic liver disorders. We did not consider gene
correction by homologous recombination as the preferred option,
as the classic approach of electroporation to introduce BACs and
deliver more than 100 kbp of gene flanking regions is accompanied
by strong DNA damage (double-strand breaks) and by offsite
integrations of part of the transferred DNA[35,36]. In addition, this
approachis ratherinefficientandcannotbe appliedto humanESor
iPS cells. The use of tailored zinc fingers attached to an
endonuclease for site-specific double-strand breaks substantially
increases the efficiency of recombination, but the flanking regions of
the repair constructs are only 0.5–1 kbp long, and therefore specific
zinc fingers need to be designed for each targeted locus [37]. As the
human FAH gene contains 14 exons and is 35 kb long, a single zinc
finger–based homologous recombination approach cannot be used
to correct the differentmutations innewborns with tyrosinemiatype
I, unless new targeting strategies are designed for each new
mutation. In the present study, we generated fully pluripotent iPS
cells from the diseased mice and established a gene-corrected iPS
cell line by transduction of an intact FAH cDNA sequence on a
third-generation self-inactivating lentiviral vector, which is much
safer in terms of oncogenic transformation than a conventional
gamma-retroviral vector [38]. This is because conventional
retroviral vectors preferentially integrate next to transcriptional
start sites and regulatory gene regions, whereas lentiviral vectors
tend to insert far away from the transcriptional regulating sites of
transcribed genes [39]. In fact, lentiviral vectors have already been
used in the clinical setting as part of the therapeutic intervention for
a variety of disease states, including advanced forms of HIV
infection, inherited disorders affecting hematopoietic cells, and
Parkinson’s disease (reviewed in [40]). The same vector architecture
as in our experiments was used in a recent gene therapy trial for X-
linked adrenoleukodystrophy [41] and is also currently used in an
ongoing multicenter trial for Wiskott-Aldrich syndrome, coordinat-
ed by the San Raffaele Telethon Institute for Gene Therapy (Milan,
Italy; meeting abstract [42]).
To date, no iPS cell–derived differentiation protocol has
succeeded in yielding transplantable cells that fulfill both crite-
ria—functional engraftment and response to proliferative stimuli in
the diseased liver—and the best evidence for functional hepatic iPS
cell–derivatives was recently demonstrated using wild-type iPS cells
to supplement FAH
2/2 blastocysts in chimeric mice [43].
Therefore, we performed tetraploid embryo complementation
experiments to demonstrate that gene correction did not affect the
pluripotent state of the iPS cells and, most importantly, that gene-
corrected iPS cells can be used to generate functional hepatocytes in
vivo that fully restore the diseased phenotype of acute liver failure
and can be stimulated to proliferate and regenerate liver tissue.
Results
Generation and Characterization of FAH
2/2-iPS Cells
Fetal fibroblasts obtained from pregnant FAH
2/2 mice on 13.5
days post-coitum (dpc) were transduced with gamma-retroviral
vectors expressing Oct4, Sox2, Klf4, and c-Myc to generate FAH
2/2-
iPS cells. Five days after retroviral transduction, FAH
2/2 cells
were replated on mouse embryonic fibroblast (MEF) feeder cells
under mouse embryonic cell culture conditions. Within 9–14 d of
transduction, we observed various distinct cell colonies. Based on
morphological criteria, we chose 16 colonies, from which we
established 8 iPS cell lines, of which we used two in our study (#4
and #7). These iPS cells stained uniformly positive for alkaline
phosphatase activity (line #7 in Figure 1A,B) and expressed the
pluripotency-associated markers Oct4, Sox2, and SSEA1
(Figure 1C–1K). Both iPS cell lines were male with a normal
karyotype and did not show any detectable chromosomal
translocations as shown by spectral karyotyping (SKY), which
allows for detection and identification of structural chromosome
Author Summary
Pluripotent stem cells have unlimited self-renewing
capability and the potential to differentiate into virtually
all cell types of the body. Pluripotent stem cells are
therefore of great interest for future cell-based therapies
and are already in use today for studying diseases ‘‘in a
dish’’ and screening for new drugs. After the seminal
discovery that induced pluripotent stem cells (iPS cells) can
be generated by the delivery of four transcription factors
into non-pluripotent cells, a tremendous amount of
enthusiasm arose about the idea that patient-derived
pluripotent stem cells could be obtained and genetically
corrected in order to develop customized therapies for
regenerative medicine. Here, we present a mouse model of
acute metabolic liver failure that fulfills such criteria. First,
we demonstrated by stringent assays that disease-specific
iPS cells exhibited full cellular and developmental potential
and the iPS cell–derived mice reproduced the phenotypes
of the founding FAH
2/2 mice faithfully. Then, we
genetically repaired the disease-specific iPS cells by
lentiviral delivery of an intact gene copy, and we
investigated the impact of this additional genetic manip-
ulation on these cells. With our analyses, we ruled out
major, and even minor, chromosomal aberrations in the
gene-corrected iPS cells. Most importantly, we demon-
strated that the gene-corrected cells maintained their full
potential and we generated viable mice that were
completely derived from these repaired cells via tetraploid
complementation approach, and these mice were healthy,
without any signs of the metabolic liver disease.
Viable Mice from Gene-Corrected iPS Cells
PLoS Biology | www.plosbiology.org 2 July 2011 | Volume 9 | Issue 7 | e1001099aberrations with a resolution of approximately 2 Mb (Figure 2A)
[44]. These results were confirmed using comparative genome
hybridization (array CGH), demonstrating no detectable sub-
chromosomal aberrations in line #7, compared with the starting
fibroblasts (Figure 2B). As the latter contained mixed cells from
both female and male fetuses, the male iPS cell line #7 depicts a
relative loss of X-chromosome signals. It is clear that these are iPS
cells, as we have never had any FAH
2/2 ES cells in our laboratory
as a potential contamination source, and we have also ruled out
contamination with other pluripotent stem cells in our lab by
genotyping the FAH
2/2 allele, as depicted in Figure S1A.
Furthermore, genomic integration of the retroviral vectors was
confirmed, and individual gene copy numbers for the reprogram-
ming vectors were determined by quantitative PCR using specific
primer sets and by normalizing to 18S ribosome gene copy
numbers (Table S1). We detected 12 and 8 retroviral insertions for
iPS cell lines #4 and #7, respectively.
Next, we investigated the silencing of the 4 reprogramming
factors in the established FAH
2/2-iPS cell line #7 (passage 9)
compared with cells harvested 3 d after retroviral transduction
with the 4 reprogramming factors (Figure S1B). Exogenous pMX
retroviral–mediated expression of Oct4, Klf4, and c-Myc was
markedly reduced to background levels, and retroviral Sox2
expression was downregulated to less than 1.8% of its initial
expression level 3 d after transduction.
However, quantitative real-time–PCR (qRT-PCR) expression
analyses revealed that the iPS cells expressed endogenous Oct4,
Nanog, and Sox2 at levels similar to those of OG2 ES cells
(Figure 2C). Global transcriptome analysis demonstrated the
complete reprogramming of FAH
2/2 fibroblasts into induced
pluripotent (FAH
2/2-iPS) cells, whose expression profile highly
correlated with that of ES cells (rlin=0.98; Figure 2D,E). Thus, the
subtle differences in gene expression levels were similar to those of
independently derived ES cell lines. Finally, DNA methylation
analysis of CpG-enriched islets in the Oct4 and Nanog promoter
regions (Figure 2F) demonstrated strong hypomethylation in both
pluripotent cell types (FAH
2/2-iPS and OG2 ES cells), which
indicates that these key factors play a role in the transcriptional
network of cellular pluripotency.
In Vivo Potential of FAH
2/2-iPS Cells
The most robust proof for pluripotency of a given stem cell line
is its ability to complement for the defective rudimentary inner
cell mass of tetraploid mouse embryos (Figure S2A–S2F). In
contrast to all previous studies, in which live pups were generated
by injecting iPS cells into tetraploid blastocysts with an efficiency
of 19%, 13%, 3.5%, and 1% [30–33], we applied the aggregation
method using tetraploid 8-cell embryos and gene-corrected iPS
cells. Using both FAH
2/2-iPS cell lines #4a n d#72, we were
able to generate fully developed pups on E19.0, when we
performed caesarean section delivery. We obtained 39 (6.1%)
fully developed live pups on E19.0 from 644 embryo aggregates
with line #4 in nine individual experiments, but 21 of the pups
failed to start breathing. Of the 18 pups that started breathing,
only one survived for 3 wk and exhibited marked growth
retardation. In contrast, iPS line #7 gave rise to many more
viable mice in three individual sets of experiments. From a total
number of 151 transferred aggregates, we obtained 43 fully
developed male, non-chimeric (by coat color) pups on E19.0 at a
surprisingly high efficiency of 28.5% (range, 21.2%–40.0%; see
Figure 3A for a subset of one experiment). A total number of 34
pups started breathing after caesarean section delivery, of which
20 (13.2%) survived to adulthood (Table 1; Figure 3B). Most of
the neonatal iPS cell–derived mice were shown, by PCR
genotyping, to have entirely originated from the iPS cells. After
35 cycles of PCR, the wild-type FAH allele was detected in seven
of 35 pups from line #4 and in 5 of 28 pups from line #7, and
the faint intensity of the band indicated a very minor contribution
of wild-type 4n cells in these mice (Figure S2G). Of the 11 adult
iPS mice genotyped, 10 were found to be derived solely from iPS
cells. Two of these 10 mice were mated with wild-type CD1
female mice to assess their fertility. We found that both male mice
were fertile, and all the 38 F1 pups obtained contained the FAH-
knockout allele (Figure S2H). In general, iPS cell–derived mice in
the present study were supplemented with NTBC (2-(2-nitro-4-
fluoromethylbenzoyl)-1,3-cyclohexanedione) in the drinking wa-
ter [45] to prevent liver failure. To evaluate the diseased
phenotype, a subset of four mice was challenged by NTBC
withdrawal. As expected, these mice showed progressive loss of
body weight, liver damage, and general lethargy within 14 d of
NTBC withdrawal. Elevated serum levels of aspartate amino-
transferase (AST, grey bars) and alanine aminotransferase (ALT,
black bars) confirmed the disease-specific phenotype (Figure 3C),
with AST and ALT levels comparable to those for original
FAH
2/2 mice ‘‘off’’ NTBC. FAH
2/2 mice, which were ‘‘on’’
NTBC, did not show elevated transaminase levels compared with
wild-type mice. Further histological analyses by hematoxylin and
eosin (H&E) staining of the liver tissue of the iPS cell–derived
mice showed severe liver damage, as indicated by swollen and
pale hepatocytes as well as by inflammatory infiltrations in the
livers of mice without NTBC treatment (Figure 3D), whereas only
subtle pathologic changes were observed in the livers of the iPS
cell–derived mice ‘‘on’’ NTBC. These findings clearly demon-
strate that the iPS cell–derived mice faithfully replicated the
phenotype of the founding FAH
2/2 mice.
Genetic Correction of FAH
2/2-iPS Cells and Generation of
Viable Mice from Gene-Corrected iPS Cells
For the genetic correction of the FAH mutation in FAH
2/2-iPS
cells, we first constructed a lentiviral vector coexpressing an intact
wild-type FAH cDNA and the reporter gene EGFP sequences
linked by a 2A-peptide motif under the transcriptional control of
a strong ubiquitously expressed viral promoter, the spleen focus-
forming virus (SFFV) promoter (Figure 4A). After transducing
FAH
2/2-iPS cell line #7 of an early passage number (p7), we
performed two rounds of subcloning to derive pure gene-
corrected FAH (FAH
gc)-iPS cell lines by picking colonies with
homologous EGFP expression and typical ES cell morphology
(Figure 4B). Quantitative RT-PCR analyses for Oct4, Nanog, and
Sox2 expression (Figure 4C) confirmed the pluripotent phenotype
of the two FAH
gc-iPS cell lines tested (#7.1 and #7.2). As
depicted in Figure 4D, global expression profiles were unaffected
by the gene correction procedure and all three tested iPS cell lines
clustered very closely—FAH
gc-iPS cell line #7.2 was slightly
closer to the parental iPS cell line #7 than was line #7.1. Both
gene-corrected cell lines (#7.1 and #7.2) and another derivative
(#7.8) did not exhibit detectable subchromosomal aberrations
and did not show aberrant copy number variations, compared
with the starting fibroblasts, as determined by array CGH
analyses (Figure 4E).
Next, we used tetraploid embryo complementation to evaluate
the developmental potential of the gene-corrected iPS cells
(Table 2). We transferred 172 aggregates comprising tetraploid
embryos and FAH
gc-iPS cells into pseudopregnant mothers and
obtained 41 fully developed male pups (23.8%) on E19.0 by
caesarean section delivery. Most of the pups generated with
FAH
gc-iPS cell line #7.1 failed to start breathing and showed
severe fetal abnormalities, with only one mouse surviving to
Viable Mice from Gene-Corrected iPS Cells
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gc-iPS mice were obtained
with FAH
gc-iPS cell line #7.2 (Figure 5A). Immunohistochemical
analyses of liver sections from the nonbreathing neonatal pups of
line #7.2 demonstrated the presence of the FAH protein in a
minority of the liver cells (Figure 5B), indicating silencing of the
FAH transgene in most of the FAH
gc-iPS–derived cells. The
absence of nonspecific staining in the FAH
2/2 livers and the
presence of evenly distributed staining in wild-type livers
confirmed the specificity and sensitivity of the antibody,
respectively (Figure 5C,D).
Figure 1. Characterization of iPS cells from FAH
2/2 mice. (A) Morphology of FAH
2/2-iPS cells (line #7) grown on MEF cells under murine
embryonic stem cell culture conditions. (B) Alkaline phosphatase activity demonstrates homogenous staining in FAH
2/2-iPS cell colonies. (C–K)
Immunofluorescence analyses for Oct4, Sox2, and SSEA1 confirms the induction of pluripotency in FAH
2/2-iPS cells. Scale bars, 100 mm in (A) and (B)
and 50 mm in (C–K).
doi:10.1371/journal.pbio.1001099.g001
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PLoS Biology | www.plosbiology.org 4 July 2011 | Volume 9 | Issue 7 | e1001099Figure 2. Molecular characterization of FAH
2/2-iPS cells. (A) SKY analysis of line #7 showed a normal male karyotype (40, XY) without any
signs of chromosomal abnormalities. Each chromosome is depicted in original fluorescence color (left) and after classification (right). (B) Array CGH
analyses of the male FAH
2/2–iPS cell line #7 compared with the sex-mixed starting fibroblast (MEF) population further conformed its normal
karyotype. (C) Quantitative RT-PCR for the pluripotency factors Oct4, Sox2, and Nanog in FAH
2/2-iPS cells compared with OG2 ES cells (normalized to
1). (D) Hierarchical clustering dendrogram of FAH
2/2-iPS cell lines based on global expression profile similarity (r: linear correlation coefficient). (E)
Scatter plot of global gene expression data comparing FAH
2/2-iPS cells with FAH
2/2-MEFs (left panel) and FAH
2/2-iPS cells with ES cells (right panel).
(F) Methylation status of Oct4- and Nanog-promoter regions in fibroblasts (starting cells: FAH
2/2-MEFs), FAH
2/2-iPS cells, and OG2 ES cells. Black
circles depict methylated CpG islets; white circles show unmethylated CpG islets.
doi:10.1371/journal.pbio.1001099.g002
Viable Mice from Gene-Corrected iPS Cells
PLoS Biology | www.plosbiology.org 5 July 2011 | Volume 9 | Issue 7 | e1001099Based on these results, we decided to maintain the foster
mothers with NTBC supplementation to ensure the subsequent
development of the FAH
gc-iPS cell–derived neonatal mice. Of the
17 breathing mice, 13 were initially accepted and fed by the foster
mothers, but of these, seven died within the first week of birth.
Nevertheless, six mice survived to adulthood (Figure 5E) and were
healthy for more than 12 mo, without any evidence for tumor
formation. Two of these six mice were kept without NTBC
supplementation during month 4 to month 12, suggesting that the
diseased phenotype was effectively rescued. In a liver biopsy (25%
hepatectomy) from a 7-wk-old FAH
gc-iPS cell–derived mouse, we
observed multiple cells that stained positive for FAH by
immunohistochemistry (Figure 5F). However, in a significant
number of cells no FAH protein could be detected. To confirm
that the FAH-positive cells were not derived from derivatives of
the host embryo or other wild-type cells, we assessed consecutive
liver sections for FAH (Figure 5G) and EGFP (Figure 5H) by
immunohistochemistry. We found that all cells that stained
positive for FAH also expressed EGFP, indicating that they were
derived from the gene-corrected iPS cells.
Functional Restoration of the Diseased Phenotype
To assess the efficacy of gene correction, we challenged the
gene-corrected iPS cell–derived mice by NTBC withdrawal. If the
diseased phenotype were fully restored, we would expect that the
non-FAH–expressing hepatocytes would all gradually die and that
the healthy FAH-expressing hepatocytes would proliferate and
repopulate the liver. Five weeks after NTBC withdrawal, all mice
appeared to be healthy, with no signs of FAH
2/2-associated
symptoms—that is, they were NTBC independent. Additionally,
by surgical liver biopsy, we confirmed the expansion of FAH-
expressing hepatocytes in the livers of these mice. Furthermore,
50%–70% of the hepatocytes in these biopsy sections stained
positive for FAH (Figure 5I), compared with 25% FAH-positive
hepatocytes in FAH
gc–iPS cell-derived mice with NTBC supple-
mentation (Figure 5F). This finding reflects a 2–3-fold increase in
FAH-positive hepatocytes in mice after NTBC withdrawal.
Gene Correction of FAH
2/2-iPS Cells with Mammalian
Tissue-Specific Promoter
We assumed that mammalian tissue-specific promoter sequenc-
es might be less susceptible to silencing, but more susceptible to
sustained transgene expression than viral promoter motifs.
Therefore, we generated two new gene-corrected iPS lines
(FAH
gc–iPS cells #7.7 and #7.8) by exchanging the viral SFFV
promoter cassette with a murine transthyretin (TTR) promoter
sequence in the lentiviral gene therapy vector. As both the EGFP
and FAH transgenes were driven by this liver-specific promoter,
the successfully transduced iPS cells could not express EGFP at the
pluripotent stage and thus could not be subcloned based on EGFP
expression. Alternatively, we randomly picked iPS cell colonies,
expanded them individually, and then screened for TTR-FAH-2A-
GFP transgene integration by PCR. As a result, we could only use
Figure 3. Viable mice derived from disease-specific FAH
2/2-iPS
cells via tetraploid embryo complementation. (A) Neonatal
FAH
2/2-iPS cell–derived pups delivered by caesarean section on
E19.0. In this particular experiment, 13 pups showed normal full-term
development, of which only one failed to initiate breathing (*). (B)
FAH
2/2-iPS mice demonstrated normal postnatal development upon
rescue of the underlying metabolic defect by NTBC supplementation.
(C) Transaminase activity of AST (grey bars) and ALT (black bars) in the
serum of untreated FAH
2/2 mice (off NTBC) indicated severe liver
damage in FAH
2/2-iPS mice #1 and #2, as well as in FAH
2/2 control
mice, compared with wild-type mice and FAH
2/2 mice treated with
NTBC (normal levels for both). (D) H&E staining depicts only mild
damage in treated FAH
2/2-iPS mouse liver (‘‘on’’ NTBC) but severe
damage in the liver of mice after NTBC withdrawal (‘‘off’’ NTBC), as
indicated by swollen and pale hepatocytes as well as by inflammatory
infiltrations, which confirmed the unaffected diseased phenotype of
FAH
2/2-iPS cell–derived mice, compared with the original FAH
2/2 mice.
Scale bars, 100 mm.
doi:10.1371/journal.pbio.1001099.g003
Viable Mice from Gene-Corrected iPS Cells
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gc-iPS cell lines (#7.7 and #7.8) of passage 13 or more for
subsequent experiments. By applying array CGH analyses, we
confirmed the absence of relevant chromosomal abnormalities in
line #7.8, as depicted in Figure 4E. Surprisingly, both lines were
robust in generating all iPS cell–derived mice. We obtained full-
term pups at an efficiency of 56.7% and 63.3% of transferred
aggregates generated with #7.7 and #7.8 iPS cells, respectively
(Table 2). Mice derived from #7.8 iPS cells showed robust
expression of the FAH-2A-EGFP transgene in the liver (Figure 5J,K)
in a small portion of hepatocytes as analyzed by FAH and EGFP
immunohistochemistry, respectively, but again the TTR promot-
er–driven transgenes were silenced in most of the hepatocytes.
This was even more evident in mice derived from #7.7 iPS cells,
with very few FAH-positive cells detected. In a subsequent
experiment, some newly weaned mice were kept without NTBC
supplementation and analyzed 4 wk later. All mice derived from
FAH
gc-iPS #7.7 appeared very weak after NTBC withdrawal and
presented characteristics of liver failure with very few FAH-
positive liver cells. In contrast, 50%–70% of cells stained positive
for FAH in the livers of mice derived from #7.8 iPS cells
(Figure 5L), similar to observations with the SFFV promoter-driven
construct. Up to now, 11 mo after NTBC withdrawal, two mice
derived from #7.8 iPS cells are still in good health, with no signs
of any FAH
2/2-associated symptoms. These findings suggest that
the number of FAH-expressing cells increased after NTBC
withdrawal—that is, the regenerative stimulus—and the cluster-
like appearance of the FAH-expressing cells (Figure 5L) indicated
the proliferation of functionally corrected cells, rather than the
reactivation of the silenced transgenes in FAH-negative cells,
which would have resulted in a more stochastic distribution of
single FAH-expressing cells. To confirm the tissue-specific
expression of the TTR promoter–driven transgene, we demon-
strated the absence of FAH expression in other tissues, such as
spleen and kidney, by immunohistology (Figure 5M).
Furthermore, the copy number of the FAH transgene in all four
FAH
gc-iPS cell lines and their liver tissue derivatives was
determined by quantitative PCR with the FAH-2A-GFP genomic
DNA construct (Figure 5N). FAH
gc-iPS cell line #7.1 had 18
integrations of the FAH-2A-GFP transgene, line #7.2 had only one
insertion, and lines #7.7 and #7.8 each had three insertions of the
gene-correction vector. The genomic DNA obtained from the
FAH
gc-iPS cell–derived liver tissue contained the same transgene
number, which also ruled out any major contamination with
tetraploid host embryo cells or non-corrected FAH
2/2-iPS cells in
the livers. FAH mRNA expression (Figure 5O) in the gene-
corrected liver tissues and in the parental FAH
gc-iPS cells was also
analyzed. With respect to the first set of experiments using the
SFFV promoter–driven construct, a constitutive FAH expression
was observed at levels of 8% (wild-type liver tissue was set as
100%) in line #7.2. Consistent with the FAH silencing in about
75% of the differentiated liver cells (Figure 5F), the overall FAH
mRNA expression in the liver of an FAH
gc-iPS cell–derived mouse
supplemented with NTBC dropped to 2.0%—that is, to 25% of
the expression level in line #7.2. The challenge of NTBC
withdrawal in FAH-positive cells resulted in a 2.8-fold increase in
FAH gene expression (5.7%) in FAH
gc-iPS cell line #7.2–derived
liver 5 wk after NTBC withdrawal. As expected, FAH expression
in the FAH
gc-iPS cell lines #7.7 and #7.8, with the liver-specific
TTR promoter, was virtually undetectable. Consistent with our
immunohistological observation, the FAH transgene was only
expressed at very low levels in the whole livers of line #7.7–
derived mice. But in liver samples from line #7.8–derived mice,
FAH was expressed at a level of 25% relative to wild-type liver in
unchallenged NTBC-treated mouse livers. In the NTBC with-
drawal group, the relative FAH expression was 207%, which
further provides strong evidence that the FAH-positive cells were
functionally responsive to the regenerative stimulus, NTBC
withdrawal, and increased in numbers by roughly 4-fold. Two of
Table 1. Experimental summary of tetraploid complementation of FAH
2/2-iPS cells compared with OG2 ES cells.
Cells Tested Experiment
Passage
Number
Aggregates
Transferred Full-Term Pups on E19
Survived to
Adulthood
Breathing Not Breathing Dead Total
FAH–/–-iPS line #41 7 2 6 0 2 0 2 0
2 8 88 2 3 0 5 0
3 8 63 0 1 0 1 0
41 0 1 2 8 2 1 0 3 0
5 7 70 2 0 0 2 0
6 8 83 5 1 1 7 0
7 8 98 3 4 1 8 1
8 5 38 1 4 0 5 0
9 7 50 3 1 2 6 0
Total 644 18 17 4 39 (6.1%) 1 (0.16%)
FAH–/–-iPS line #71 7 4 5 1 2 1 0 1 3 4
2 7 40 13 3 0 16 9
39 6 6 9 5 0 1 4 7
Total 151 34 9 0 43 (28.5%) 20 (13.2%)
OG2 ES 1 7 36 10 1 1 12 8
2 7 50 10 4 0 14 7
Total 86 20 5 1 26 (30.2%) 15 (17.4%)
doi:10.1371/journal.pbio.1001099.t001
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2/2-iPScells.(A)DesignofthelentiviralconstructforgenecorrectionofFAH
2/2cells:AnintactFAHcDNAwasexpressed
in conjunction with EGFP, linked by a 2A-peptidase motif (P2A) for coexpression, under the transcriptional control of the spleen focus-forming virus( SFFV)
promoter. (B) After transduction of FAH
2/2-iPS cells in single-cell suspension, colonies showing homogenous EGFP expression were subcloned. A second
subcloningstepwasappliedtoensureclonalityofthegene-correctedFAH
gc-iPScelllines,asdepictedforline#7.2.Scalebars,100 mm.(C)QuantitativeRT-PCRfor
the pluripotency factors Oct4,Sox2,a n dNanog in FAH
gc-iPS cells (#7.1 and #7.2) compared with OG2 ES cells (normalized to 1). (D) Scatter plot of global gene
expression data comparing FAH
gc-iPS cell line #7.2 with FAH
2/2-iPS cell line #7, and dendrogram of the indicated samples based on global expression profile
similarity (r: linear correlation coefficient). (E) Array CGH analyses of the male gene-corrected FAH
gc–iPS cell lines #7.1, #7.2, and #7.8 showed no detectable
chromosomal aberrations, compared with the sex-mixed starting fibroblast (MEF) population.
doi:10.1371/journal.pbio.1001099.g004
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2/2
phenotype, demonstrating the full functional restoration of the
FAH deficiency in the gene-corrected iPS cell line #7.8.
Discussion
Although entirely mouse iPS cell–derived mice have been
generated [30–33], iPS cells carrying a disease-specific genetic
defect have not yet been shown to retain full pluripotency upon
genetic correction and prolonged propagation, as well as to ‘‘pass’’
stringent tests for pluripotency. In our study, we were able to
generate metabolic liver disease–specific iPS cells from fetal
fibroblasts of FAH
2/2 mice [34] and to maintain various clonal
lines that show all phenotypic hallmarks of pluripotent stem cells,
as seen for line #7 in Figures 1 and 2.
For the initial tetraploid embryo complementation experiments,
we chose two independent FAH
2/2-iPS cell lines (#4 and #7),
which gave rise to different results as summarized in Table 1. The
FAH
2/2-iPS cell line #7 yielded up to a 28.5% efficiency in
generating full-term pups by aggregation of iPS cells with a
tetraploid morula in a sandwich manner, which was even hardly
achievable with advanced protocols using normal ES cells [46].
The gene-corrected iPS cells of line #7.2 gave rise to 21 (22.1%)
full-term pups, of which 6 (6.3%) developed into adult mice. Using
the gene-corrected iPS lines #7.7 and #7.8, the efficiency of
obtaining full-term pups (and adult mice) was even higher,
reaching 56.7% (and 20.0%) and 63.3% (and 36.7%), respectively,
probably due to the multiple selection steps during the gene
transfection process. This efficiency is in the very same high range
of normal ES cell aggregates and it is much higher than the
efficiency for iPS cells per recent reports: 0.53% [31], 3.5% [32],
and 2% and 7% [30]. A possible explanation for the higher
efficiency is that, unlike all these reports, we did not use the
blastocyst injection method for generating iPS cell–derived mice,
but exclusively used the morula aggregation method with selected
colonies of iPS cells that showed the most intact colony
morphology. We speculate that other groups have used different
criteria to identify and process iPS or ES cells. As the presence of
discriminating markers [33] for bona fide pluripotent iPS cells
have been suggested to correlate with pluripotency, it is unclear
whether remnants of an epigenetic memory account for the
markedly less efficient full-term pup development in the other
tetraploid embryo complementation studies using fibroblast-
derived iPS cells [30–32]. Nevertheless, our results demonstrate
that morula aggregation is a simple and highly efficient approach
to generate entirely iPS cell–derived mice via iPS cell/tetraploid
embryo complementation.
With our data, we clearly demonstrated that our murine iPS
cells (line #7 and its derivatives) were equivalent to ES cells, by the
most stringent test for pluripotency—tetraploid embryo comple-
mentation. The reduction in the number of reprogramming
factors for the generation of iPS cells [47–49] is considered to be
beneficial for iPS cell generation and is expected to obviate
limitations related to chromosomal transgene integrations. How-
ever, despite numerous attempts using our 2-factor and 1-factor
iPS cells [50], we have not yet been able to successfully complete
tetraploid embryo aggregation. It would be interesting to discover
the underlying molecular differences between the lines, which
would lead to a better understanding of pluripotency and might
allow for the identification, by simple marker gene expression, of
high-quality iPS cell lines for future clinical applications. In our set
of experiments, the gene expression profile of the less successful
FAH
2/2-iPS cell line #4 clustered very closely to that of the high-
quality line #7 (Figure 2D), and we only detected significant
differences in very few genes (Jarid1d, Erdr1, Eif2s3y). However, a
comparison of only these two independent iPS cell lines (#4 and
#7) may not identify differentially expressed genes and predict
fully pluripotent iPS cells that can pass the tetraploid embryo
complementation test. Aiming to identify such discriminating
transcripts, the Dlk1-Dio cluster (on the long arm of chromosome
12) was recently reported to carry a few imprinted genes that
exhibit a distinct differential expression pattern in fully pluripotent
ES cells compared with iPS cells [33], with these genes suggested
as candidate markers for selection of high-quality iPS cell lines.
However, in our study, we could not find significant differences in
Dlk1, Gtl2, and Rian expression among our FAH
2/2-iPS cell lines,
which actually all gave rise to full-term iPS cell–derived pups but
supported various degrees of postnatal development. Postnatal
developmental failure was observed in FAH
2/2-iPS line #4 and
#7.1–derived mice. As an alternative explanation, the four
additional insertions of the reprogramming factors found in line
#4 (Table S1) and the high transgene copy number detected in
line #7.1 may account for the different outcomes in our study.
The development of iPS cell–based transplantation approaches
for the treatment for genetic disorders must comprise a gene-
correction strategy for rescuing the diseased phenotype [51]. The
genetic engineering of ES and iPS cells appears to be rather
inefficient, but recently published studies on a targeted genetic
engineering approach show promise [37,52]. As outlined above,
the safety issues associated with using electroporation to deliver
Table 2. Experimental summary of FAH
gc-iPS cell tetraploid complementation.
Cells Tested Experiment
Passage
Number
Aggregates
transferred Full-Term Pups on E19
Survived to
Adulthood
Breathing Not Breathing Dead Total
Line #7.1 (SFFV) 1 11 50 1 5 1 7 0
21 2 2 74 9 0 1 3 1
Total 77 5 14 1 20 (26.0%) 1 (1.3%)
Line #7.2 (SFFV) 1 11 39 5 3 0 8 2
2 1 25 6 1 21 0 1 3 4
Total 95 17 4 0 21 (22.1%) 6 (6.3%)
#7.7 (TTR) 1 (Total) 13 30 15 2 0 17 (56.7%) 6 (20.0%)
Line #7.8 (TTR) 1 (Total) 13 30 19 2 0 21 (63.3%) 11 (36.7%)
doi:10.1371/journal.pbio.1001099.t002
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PLoS Biology | www.plosbiology.org 9 July 2011 | Volume 9 | Issue 7 | e1001099Figure5.Viable mice derived from gene-corrected FAH
gc-iPS cells viatetraploid embryo complementation.(A) A representative litter ofFAH
gc-
IPS cell–derived neonatal pups. One of the pups failed to initiative breathing (*) after caesarean section delivery on E19.0. (B) Immunohistologicals t a i n i n gf o r
FAH demonstrated that about 20% of the hepatocytes in a newborn’s liver expressed the FAH protein. (C) FAH
2/2 liver tissue without gene correction was
used as a negative control, confirming the specificity of the antibody staining. (D) Wild-type liver was used as a positive control to confirm the sensitivity of
the FAH immunohistochemistry. All hepatocytes, but no endothelial or blood cells, stained positive for FAH. (E) Two healthy #7.2 (SFFV promoter) FAH
gc-iPS
cell–derived mice under supplementation with NTBC. (F and G) FAH staining on the liver of these mice in (E) indicated FAH expression in about 25% of the
liver cells. (H) Immunohistochemistry counterstaining for EGFP demonstrated that all FAH-positive cells in panel (G) also stained positive for EGFP. (I) FAH
staining in #7.2 (SFFV promoter) FAH
gc-iPS cell–derived mouse liver 5 wk after NTBC withdrawal showed FAH expression in most of the liver cells. (J) FAH
staining in #7.8 (TTR promoter) FAH
gc-iPS cell–derived mouse liver indicates FAH expression in about 15% of the liver cells. (K) Immunohistochemistry
counterstaining for EGFP demonstrates that all FAH-positive cells in panel J also stained positive for EGFP. (L) FAH staining in #7.8 (TTR promoter) FAH
gc-iPS
cell–derived mouse liver 4 wk after NTBC withdrawal indicates FAH expression in most of the liver cells. (M) Absence of FAH-positive staining in a kidney
sample of iPS line #7 . 8 – d e r i v e dm i c ec o n f i r m e dt h et i s s u es p e c i f i c i t yo ft h eh e p a t i cTTR promoter. (N) Estimated gene copy numbers of the FAH-P2a-EGFP
construct in both FAH
gc-iPS cell lines #7.1 and #7 . 2a sw e l la si nl i v e rt i s s u eo fa nFAH
gc-iPS cell #7.2–derived mouse. (O) FAH mRNA expression levels relative
to adult liver tissue (set as 100%) in FAH
gc-iPS cell lines and in liver samples of an FAH
gc-iPS cell–derived mouse (‘‘on’’ and ‘‘off’’ NTBC). Scale bars, 100 mm.
doi:10.1371/journal.pbio.1001099.g005
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gene locus have not yet been addressed, as severe DNA double-
strand breaks are expected [35,36]. The more sophisticated
tailored zinc finger nuclease–mediated homologous recombination
is considered to be a versatile tool for gene therapy of genetic
diseases with a single common mutation among patients, such as
cystic fibrosis (D508, Phe508del), sickle cell anemia (Glu6Val), or
a1-antitrypsin deficiency (Glu342Lys). However, various missense,
nonsense, and splice-site mutations, along with small deletions in
the FAH locus, have been reported among patients with
tyrosinemia type I syndrome—a condition considered as repre-
sentative for many orphan diseases. Unfortunately, the develop-
ment of gene therapeutic strategies for these diseases has been
relegated to academic research groups. For such disease entities,
an additive gene transfer strategy provided by a stable integration
of an intact gene copy is the preferred approach. Third-generation
self-inactivating lentiviral vectors, which are significantly safer than
conventional gamma-retroviral vectors, are now available for gene
therapy applications [40,41]. For example, lentiviral gene
correction was successfully accomplished in fibroblast cells prior
to generating Fanconi’s anemia–specific iPS cells [17]. In the
present study, we chose such a lentiviral vector with insertion of
the intact FAH cDNA and EGFP sequences linked by a 2A-
peptidase motif, which allowed for fluorescence–based selection of
FAH-expressing iPS cells to generate pure clonal gene-corrected
FAH
gc-iPS cell lines. To investigate the effects of the gene dosage
on pluripotency, we analyzed two independent clonal lines—one
with high EGFP expression and 18 copies of the FAH transgene
(line #7.1) and one with moderate EGFP expression and only one
copy of the transgene (line #7.2). When we performed tetraploid
embryo complementation with cells of line #7.1, even though the
efficiency of obtaining full-term neonatal iPS cell–derived pups
was high (26.0%), most of the iPS cell–derived pups exhibited
malformations and could not start breathing, and only one
survived to adulthood (1.3%, Table 2). However, using line #7.2,
we were able to obtain 17 breathing pups of 21 fully developed
pups from 95 transferred aggregates (Figure 5A), of which 6
survived to adulthood. However, in contrast to this dramatic
difference in postnatal developmental potential, we could not
observe significant differences in the global gene expression
pattern between lines #7.1 and #7.2, as depicted in the
dendrogram in Figure 4D. The correlation between postnatal
developmental failure and increased copy number of transgene
integration indicated the presence of lentiviral genotoxicity, which
deserves further study to identify differentially expressed genes or
discriminating (epi)genetic marks among gene-corrected iPS cells
and their relation to postnatal development.
The FAH
2/2 mouse model has been well established for
analyses of gene therapy strategies [53–56] and cell transplantation
approaches [57–59] of metabolic liver disorders, but to date, no
ES cell–based approach has demonstrated success in rescuing the
diseased phenotype. A very recent study took advantage of
generating diploid chimeras of wild-type iPS cells and FAH
2/2
embryos to prove the ability of iPS cells to give rise to functional
and transplantable hepatocytes in vivo [43]. Such an approach
could not be used to establish a disease model from somatic cell–
derived iPS cells or to investigate genetic manipulation for genetic
repair in disease-modeled iPS cells. Using the lentiviral vector
approach to express the intact FAH cDNA sequence in FAH
2/2
iPS cells, we observed silencing of the FAH-repair cassette in a
significant proportion of the hepatocytes from fetal and adult iPS
cell–derived mice (Figure 5B,F–L). Such silencing of the lentiviral
gene repair construct was also reported for Fanconi’s anemia–
specific iPS cells [17]. However, when we challenged FAH
gc-iPS
cell–derived mice by NTBC withdrawal, we found a clear increase
in the number of FAH-positive hepatocytes (Figure 5I,L), and
accordingly a 2.7-fold increase in the FAH gene expression level by
quantitative RT-PCR (Figure 5O). The long-term survival, more
than 12 mo, of these FAH
gc-iPS cell–derived mice without NTBC
supplementation provided unequivocal evidence for the efficacy of
the gene correction approach in our study. The coexpression of
EGFP in all FAH-expressing cells (Figure 5G&H, J&K) excluded
the possibility that FAH
2/2 phenotypes in the FAH
gc-iPS cell–
derived mice were actually rescued by the residual wild-type cells
from the host 4n embryos. With these findings, we demonstrate for
the first time that gene-corrected iPS cells could give rise to
hepatocytes that both respond to proliferative stimuli and are
capable of restoring liver function. However, our findings also
suggest that lentiviral gene repair constructs introduced into iPS
cells are highly susceptible to silencing. This undesirable silencing
was evident with either a strong viral promoter motif (SFFV)o ra
mammalian tissue-specific promoter sequence (TTR), and it could
be overcome if a selective pressure was present for the transgene-
expressing cells.
In conclusion, metabolic liver disease–specific iPS cells obtained
from reprogrammed somatic cells can be gene corrected to
generate entirely iPS cell–derived healthy mice using the highly
efficient tetraploid embryo complementation approach. With our
data, we demonstrate that a life-threatening genetic disease can be
treated via an iPS cell approach. As this approach can lead to a
functional organism, we would expect that fully functional cells
could be generated and used for transplantation purposes.
Materials and Methods
Ethics Statement
All animal experiments were performed according to protocols
approved by the local authorities. All our mice had free access to
food and water and were handled in accordance with institutional
guidelines.
Cell Culture and Generation of FAH-iPS Cells
Mouse embryonic stem cells (OG2 ES) carrying an Oct4-GFP
reporter construct [60] and induced pluripotent stem (iPS) cells
were cultured according to standard conditions [61]. pMX-based
retroviral vectors encoding the mouse complementary DNAs for
Oct4, Sox2, Klf4, and c-Myc [2] were cotransfected with packaging-
defective helper plasmids into 293T cells using FuGENE 6
Transfection Reagent (Roche, Mannheim, Germany) as described
previously [47]. Virus-containing supernatants were collected 48 h
later. Fetal fibroblasts obtained from pregnant C57BL/6 FAH
2/2
mice (provided by Arndt Vogel, Hannover Medical School) on
E13.5 were seeded at a density of 5610
4 cells per well of a 6-well
plate and incubated with virus-containing supernatants of the 4
factors (1:1:1:1) supplemented with 6 mgm l
21 protamine sulfate
(Sigma, Munich, Germany) for 24 h.
Characterization of iPS Cells
FAH
2/2-iPS cells grown on feeder cells were fixed in 80% (v/v)
methanol (Sigma) for 30 min, before staining (overnight at 4uC)
with mouse anti-Oct4, rabbit anti-Sox2 (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA), or biotinylated mouse anti-
SSEA1 (1:300; eBioscience, San Diego, CA). Nuclei were labeled
with DAPI (Sigma) and Cy3-conjugated rabbit anti-mouse IgG;
FITC-conjugated goat anti-rabbit IgG (1:300; Jackson ImmunoR-
esearch, Newmarket, Suffolk, UK) and FITC-Streptavidin (1:200;
eBioscience) were used as secondary reagents. Alkaline phospha-
tase staining was performed with Alkaline Phosphatase Detection
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instructions.
For spectral karyotyping (SKY), metaphase chromosomes were
prepared using standard protocols. In brief, cells were treated with
colcemid at a final concentration of 0.035 mgm l
21 overnight,
incubated in 0.075M KCl for 20 min at 37uC, and fixed in a
freshly prepared mixture of methanol:acetic acid (3:1) at room
temperature. The cell suspension was dropped onto glass slides in
a climate chamber (Polymer, Kassel, Germany) at 22uC and 48%
humidity. SKY analysis was performed as described previously
[44]. Spectral images were acquired using an epifluorescence
microscope equipped with an interferometer (SpectraCube ASI), a
custom-designed optical filter, and the SkyView software (ASI).
Array CGH was performed using the Agilent oligonucleotide-
based Mouse Genome Microarray Kit 46180 k (G4839A, Agilent
Technologies, Santa Clara, CA, USA). Labeling and hybridization
of genomic DNA was performed according to the protocol
provided by Agilent. Briefly; 1.5 mg of test DNA (FAH-iPS) and
reference DNA (mixed FAH-MEF cells from male and female
fetuses) were labeled by random priming using the Agilent
Genomic DNA Labeling Kit Plus, test DNA with Cy3-dUTP,
and reference DNA with Cy5-dUTP. Labeled products were
purified by Amicon ultra-0.5 ml 30K filters (Millipore, Billerica,
MA, USA), combined, and then mixed with Mouse Cot-1 DNA
(50 mg), Agilent 10X Blocking Agent, and Agilent 2X Hybridiza-
tion Buffer. This solution was hybridized to Agilent’s 46180 k
Mouse Genome CGH microarray at 65uC with 20 rpm rotation
for 40 h. Washing steps were performed according to the Agilent
protocol. Microarray slides were scanned immediately using an
Agilent microarray scanner. For image analysis, default CGH
settings of Feature Extraction (FE) Software 10.10.1.1 (Agilent
Technologies, Waldbronn, Germany) were applied. Output files
from FE were subsequently imported into Agilent’s CGH data
analysis software, Genomic workbench 6.5. for DNA copy number
analysis using ADM-2 (aberration detection module) algorithm set
to threshold of 6.0 and aberration filter set to 10 probes with mean
log2 ratio of 0.4.
FAH transgene copy numbers were determined using primers
for the lentiviral backbone (forward: 59-GAG GAG TTG TGG
CCC GTT GT-39; reverse: 59-TGA CAG GTG GTG GCA ATG
CC-39). The retroviral-specific primers consist of a common sense
primer (59- CTT GAA CCT CCT CGT TCG AC-39) located
upstream of each transgene within the retroviral backbone and a
gene-specific antisense primer (Oct4: 59-CTC CGC AGA ACT
CGT ATG C-39; Sox2: 59-GGG CTG TTC TTC TGG TTG C-
39; Klf4: 59-ACG CAG TGT CTT CTC CCT TC-39; and c-Myc:
59-TCC TCG TCG CAG ATG AAA TAG-39). For normaliza-
tion, 18S ribosome gene copy number (200 copies in murine cells
[62]) was used with the primer pair 59-AGG GCA GGG ACT
TAA TCA ACG C-39 and 59-GTT GGT GGA CCG ATT TGT
CTG G-39.
Gene Expression Analyses
Total RNA was isolated using TRIzol reagent (Invitrogen,
Karlsruhe, Germany) and the resultant RNA was subjected to DNase
treatment and cDNA transcription (SuperScript III cDNA synthesis
kit, Invitrogen) to perform qRT-PCR (StepOne plus Cycler, Applied
Biosystems, Darmstadt, Germany). We used TaqMan Assays-on-
Demand for Oct4 (Mm00658129_gH), Sox2 (Mm00488369_s1),
Nanog (Mm02019550_s1), Fah (Mm01312827_m1), and b-actin
(Mm00607939_s1) for normalization.
Total RNA samples to be hybridized on Illumina mouse-8 V2
expression BeadChips were processed using a linear amplification
kit (Illumina TotalPrep RNA Amplification Kit, Ambion)
generating biotin-labeled cRNA. After assessing its quality on a
2100 Bioanalyzer (Agilent), RNA was hybridized as recommended
and using materials/reagents provided by the manufacturer.
Background subtraction, data normalization (cubic spline algo-
rithm), and global expression profile comparisons were carried out
using BeadStudio. All raw and processed microarray data have
been submitted to Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE21343, in a MIAME-compliant format.
For real-time analysis of the pMX-driven expression of the four
factors, RNA from iPS cells was extracted using the RNeasy Mini
Kit (QIAGEN, Hilden, Germany), following the manufacturer’s
instructions. Complementary DNA synthesis was performed with
the High Capacity cDNA Archive Kit (Applied Biosystems)
following the manufacturer’s instructions. Transcript levels were
determined using the ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems) and custom oligonucleotides for the
59-nuclease assay, which can amplify the viral transcripts but not
the endogenous ones [47]. The expression of the viral factors was
normalized to the endogenous Hprt1 gene (Mm00446968_m1,
from Applied Biosystems), using the DDCT method.
DNA methylation was analyzed by bisulfite treatment and
sequencing of the promoter regions of Oct4 and Nanog as described
previously [63]. For gene copy number analyses, genomic DNA
was isolated using GenElute Mammalian Genomic DNA Mini-
prep Kit (Sigma) according to the manufacturer’s instructions.
Quantitative PCR was performed on three technical replicates
using PCR Master-Mix (Peqlab Biotechnology) supplemented with
SYBR green (Lonza, Rockland, ME) on a StepOne plus Cycler
(Applied Biosystems).
Analyses of the FAH
2/2 Phenotype
FAH
2/2 mice were maintained by supplementation of drinking
water with 2-(2-nitro-4- trifluoromethylbenzoyl)-1,3-cyclohexane-
dione (NTBC, 4 mg ml
21, from Swedish Orphan International,
Stockholm, Sweden). For determination of the liver enzyme
activity, heparinized blood samples were collected from mice and
centrifuged at 3,000 rpm for 10 min. Sera were stored in a 220uC
refrigerator. ALT and AST levels were analyzed in a routine
laboratory with an automatic analyzer (Vitros 5.1, Ortho, France).
For liver biopsy, mice were anesthetized with isoflurane before a
partial hepatectomy was performed in which 25% of liver was
removed. The left lateral lobe was tied to block the blood supply
before surgical removal of the intact lobe.
For immunohistochemistry analyses, paraffin-embedded liver
tissue was processed for H&E staining according to standard
protocols. For FAH staining, endogenous peroxidase was blocked
with 3% hydrogen peroxide in methanol for 10 min, followed by
antigen retrieval in target retrieval solution (Dako, Glostrup,
Denmark) for 20 min in a water bath at 98uC. Next, the sections
were serially incubated with avidin/biotin block and 20% goat
serum (Vector Laboratories, Burlingame, CA) for 15 min at room
temperature, and then with primary antibody rabbit polyclonal
anti-FAH (IgNex, 1:400) or primary antibody rabbit polyclonal
anti-GFP (Invitrogen, 1:250) overnight at 4uC. The sections were
then serially incubated with secondary antibody biotinylated goat
anti-rabbit (1:700) as well as EliteA and B (Vector Laboratories) for
1 h at room temperature, to allow enzyme complex formation and
thus color development with 3-amino-9-ethylcarbazole (Dako).
Sections were counterstained with Gill’s No. 3 hematoxylin.
ALT and AST levels were analyzed in a routine laboratory with
an automatic analyzer (Vitros 5.1, Ortho, France).
Genotyping of the FAH
2/2-iPS cells and FAH
2/2-iPS cell–
derived mice was performed on genomic DNA isolated from the
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2/2-iPS cells, OG2 ES cells, and murine tail tips as reported
previously [34].
Generation of a Lentiviral Gene–Correction Construct
The self-inactivating (SIN) lentiviral vector pRRL.PPT.SFFV.FA-
H.2A.EGFP.Pre* was created based on pRRL.PPT.SFFV.EGFP.Pre*
[64,65]. Primers containing complementary restriction sites to the
opened vector backbone as well as a Kozak consensus sequence
were used to amplify murine FAH cDNA from plasmid
IRAVp968E0631D (imaGenes, Berlin, Germany). The reverse
primer deleted the stop codon of FAH cDNA to enable translation
of a fusion protein in the final vector construct. The EGFP
fragment of the lentiviral vector pRRL.PPT.SFFV.EGFP.Pre*
plasmid was replaced with FAH cDNA. This vector
pRRL.PPT.SFFV.FAH.Pre* was opened by restriction digestion for
a second cloning step. Primers containing restriction sites as well as
the sequence of the Porcine Teschovirus 2A oligopeptide [66]
were used to amplify a 2A-EGFP sequence and cloned into the
opened vector backbone. The final vector construct contains a self-
inactivating lentiviral vector expressing a fusion mRNA of FAH
and EGFP. 2A peptide results in the cotranslational ‘‘cleavage’’ of
the fusion protein and is an alternative to the internal ribosomal
entry site. 2A peptides were shown to lead to expression of
multiple cistrons at equimolar levels [67]. The vector
pRRL.PPT.TTR.FAH.2A.EGFP.Pre* was created by replacing the
promoter sequence from pRRL.PPT.SFFV.FAH.2A.EGFP.Pre* with
the mini-transthyretin (TTR) promoter kindly provided by Dr.
Weidong Xiao, Temple University, PA (PMID: 18500941). FAH
expression was validated by RT-PCR and Western blot. Cloning
details, vector maps, and sequence files are available upon request.
Gene Correction of FAH
2/2-iPS Cells
Single-cell suspension (10,000 FAH
2/2 iPS cells, passage 7) was
transduced with infectious particles of pRRL.PPT.SFFV.FA-
H.2A.EGFP.Pre*o rpRRL.PPT.TTR.FAH.2A.EGFP.Pre* lentivirus
(MOI=100) in a volume of 50 ml (mESC medium supplemented
with 10 mgm l
21 protamine sulfate [Sigma] and double concen-
tration of LIF), and covered with mineral oil (Sigma). Following
incubation for 8 h at 37uC in a humidified environment at 5%
CO2, the cell suspension was transferred into a 6-cm dish with
fresh MEFs and mouse ES cell medium.
Supporting Information
Figure S1 Characterization of FAH
2/2-iPS cells. (a) Specific
PCR primers discriminating the FAH-knockout (KO) allele from
the wild-type (Wt) allele confirmed the FAH
2/2 genotype in
FAH
2/2-iPS cells. A weak Wt band was detected in the second
lane, which was due to contamination with feeder cells (MEFs).
This band was eliminated by manually picking the iPS cell colonies
prior to DNA isolation (the third lane). (b) Efficient silencing of
gamma retrovirus–mediated expression of the reprogramming
factors in FAH
2/2-iPS cells. Expression levels in freshly transduced
cells (day 3) were set to 1.
(TIF)
Figure S2 Tetraploid embryo complementation using FAH
2/2-
iPS cells. (a) Two-cell embryos were flushed from 2.5-dpc mice.
Scale bar, 100 mm. (b) To produce 4n embryos, 2-cell embryos
were fused using electrofusion. Scale bar, 100 mm. (c) Com-
pacting 4-cell embryos were observed 24 h after fusion. Scale
bar, 100 mm. (d) The zonae pellucidae of the 4-cell embryos
were removed by acidified Tyrode’s solution and aggregated in
pair with FAH
2/2-iPS cells. Scale bar, 50 mm. (e) The chimeric
embryos developed to the blastocyst stage in culture overnight
and were then transferred into the uterus of pseudopregnant
mice. Scale bar, 50 mm. (f) FAH
2/2-iPS mice with their CD1
foster mother. Note the complete black fur color of these mice,
in contrast to the brown fur color of the 4n host embryos. (g)
Genotyping of the FAH
2/2 allele (KO) and the wild-type allele
(Wt) in pups that were derived from FAH
2/2-iPS cells. Eight of
12 pups were shown to be entirely derived from FAH
2/2-iPS
cells. Four of the pups showed very mild contribution from the
residual Wt cells of the 4n host embryos. (h) Genotyping of the
FAH
2/2 allele (KO) and the wild-type allele (Wt) in the F1
offspring resulting from the mating of FAH
2/2-iPS cell–derived
male mice with wild-type female mice.
(TIF)
Table S1 Copy numbers per genome for each reprogramming
factor in the FAH
2/2-iPS cells.
(TIF)
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